Articles
| Open Access |
https://doi.org/10.55640/
“THE ROLE OF ALPHA-ADRENERGIC BLOCKERS IN THE TREATMENT OF URINARY DISORDERS IN NEUROLOGICAL AND UROLOGICAL PATIENTS”
Ruzmetova Guzal Melsovna,Saminova Malikakhan , is a senior lecturer at the Department of Sciences of the Clinic. at emu university The direction of treatment work 1st course,at emu universityAbstract
Urinary disorders are highly prevalent in patients with neurological and urological diseases and significantly reduce quality of life. The process of micturition is regulated by complex interactions between the central and peripheral nervous systems. Disruption of these pathways can lead to conditions such as neurogenic bladder, functional bladder outlet obstruction, or lower urinary tract symptoms (LUTS).
Keywords
alpha-adrenergic blockers, urinary disorders, lower urinary tract symptoms, neurogenic bladder, pharmacotherapy
References
Abrams P, Cardozo L, Wagg A, Wein A. Incontinence. 6th ed. International Continence Society; 2018.
Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on male LUTS. Eur Urol. 2018;74(1):109–119.
Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments. Nat Rev Urol. 2017;14(7):403–415.
Chapple CR, Roehrborn CG. A shifted paradigm for LUTS treatment. Eur Urol. 2019;75(4):593–601.
Kim DK, Lee JY, Jung JH, et al. Alpha-1 blockers for female LUTS: systematic review and meta-analysis. Int Neurourol J. 2019;23(1):56–68.
Gomelsky A, Kelly EF, Dalton DC. Combination therapy with α-blockers and anticholinergics. Curr Opin Urol. 2018;28(3):277–283.
Oelke M, et al. EAU Guidelines on non-neurogenic male LUTS. Eur Urol. 2020;77(1):63–73.
McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline for BPH. J Urol. 2021;206(4):806–826.
Gacci M, et al. Critical analysis of α-blockers in LUTS. Eur Urol. 2018;74(5):617–629.
Drake MJ, et al. Neural control of the lower urinary tract. Nat Rev Urol. 2018;15(3):133–147.
Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in neurological disease. Lancet Neurol. 2019;18(7):720–732.
Wagg A, et al. Management of urinary incontinence in older people. Lancet. 2019;393(10171):621–633.
Yamaguchi O, et al. Beta3-adrenoceptor agonists vs alpha-blockers. Neurourol Urodyn. 2020;39(2):623–630.
Sacco E, et al. Silodosin vs tamsulosin in LUTS. Urology. 2018;111:183–189.
Tubaro A, et al. Pharmacological management of LUTS/BPH. Eur Urol Suppl. 2019;18(1):1–12.
Gravas S, et al. EAU Guidelines 2022 on LUTS. Eur Urol. 2022.
Cornu JN, et al. Systematic review of α-blockers for LUTS. Eur Urol. 2018;73(5):811–829.
Foster HE, et al. Surgical and medical management of BPH. J Urol. 2019;202(3):592–598.
Chancellor MB, Yoshimura N. Neurophysiology of bladder function. Rev Urol. 2019;21(2):85–92.
Kay GG, Ebinger U. Preserving cognitive function in LUTS treatment. BJU Int. 2020;125(2):197–207.
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.